Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for re-eradication for gastric Helicobacter pylori infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Buddhist Tzu Chi General Hospital
• Treatments: Acetylcysteine; Clarithromycin; Metronidazole; Rabeprazole

Criteria

Inclusion Criteria:

• Patient after treatment for Helicobacter pylori eradication.

• Still clinically with evidence of gastric Helicobacter pylori infection.

Exclusion Criteria:

• woman in breast feeding or pregnancy.

• allergy to drugs used in study.

• never treated for H. pylori.

• intolerance to fructose, lactose.

• patients with hematologic, brain or spinal disorders.

• patients under 20 years old.

• patients with malignancy or with decompensated function of vital organs.